Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Gastroenterology. 2018 Jan 6;154(5):1320–1333.e10. doi: 10.1053/j.gastro.2018.01.002

Table 2.

Associations between derived IgG Fc-glycosylation traits and IBD in the ITA cohort.

HC vs. UCb HC vs. CD UC vs. CD
Derived traita Description OR (95% CI)c p-valued OR (95% CI) p-value OR (95% CI) p-value
IgG1

IgG1_agal Fraction of agalactosylated glycans 1.29 (1.13 – 1.47) 8.9E-05 1.69 (1.46 – 1.96) 2.2E-13 1.23 (1.11 – 1.36) 3.9E-05
IgG1_digal Fraction of digalactosylated glycans 0.88 (0.77 – 1.00) 5.7E-02 0.61 (0.52 – 0.70) 2.7E-12 0.71 (0.64 – 0.79) 8.0E-11
IgG1_monogal Fraction of monogalactosylated glycans 0.69 (0.61 – 0.79) 5.4E-09 0.69 (0.61 – 0.79) 4.3E-08 1.06 (0.97 – 1.17) 2.0E-01
IgG1_sial Fraction of sialylated glycans 1.05 (0.93 – 1.20) 4.1E-01 0.81 (0.70 – 0.92) 1.4E-03 0.78 (0.71 – 0.87) 1.5E-06
IgG1_A2B Bisection of diantennary glycans 0.69 (0.61 – 0.78) 3.5E-09 0.91 (0.79 – 1.03) 1.4E-01 1.22 (1.11 – 1.35) 7.8E-05
IgG1_A2F Fucosylation of diantennary glycans 0.93 (0.82 – 1.04) 2.1E-01 1.27 (1.12 – 1.44) 2.2E-04 1.36 (1.23 – 1.51) 6.0E-10
IgG1_A2G Galactosylation per antenna on diantennary glycans 0.81 (0.71 – 0.92) 1.5E-03 0.59 (0.51 – 0.69) 3.2E-13 0.77 (0.69 – 0.85) 2.5E-07
IgG1_A2S Sialylation per antenna on diantennary glycans 1.04 (0.92 – 1.18) 5.1E-01 0.78 (0.68 – 0.90) 3.2E-04 0.77 (0.70 – 0.85) 3.7E-07
IgG1_A2GS Sialylation per galactose on diantennary glycans 1.33 (1.18 – 1.51) 3.6E-06 1.15 (1.01 – 1.30) 3.1E-02 0.85 (0.77 – 0.94) 1.1E-03

IgG23

IgG23_agal Fraction of agalactosylated glycans 1.30 (1.14 – 1.50) 1.3E-04 2.76 (2.31 – 3.29) 1.7E-37 2.11 (1.87 – 2.37) 1.2E-40
IgG23_digal Fraction of digalactosylated glycans 0.82 (0.71 – 0.94) 3.7E-03 0.41 (0.35 – 0.48) 2.2E-31 0.49 (0.43 – 0.55) 1.0E-36
IgG23_monogal Fraction of monogalactosylated glycans 0.77 (0.67 – 0.87) 4.1E-05 0.39 (0.32 – 0.46) 8.5E-34 0.54 (0.48 – 0.60) 8.2E-32
IgG23_sial Fraction of sialylated glycans 0.87 (0.76 – 0.99) 2.9E-02 0.53 (0.46 – 0.61) 6.8E-20 0.58 (0.52 – 0.64) 1.0E-24
IgG23_A2B Bisection of diantennary glycans 0.62 (0.55 – 0.71) 3.2E-13 0.91 (0.80 – 1.05) 1.9E-01 1.34 (1.21 – 1.48) 8.2E-09
IgG23_A2F Fucosylation of diantennary glycans 0.72 (0.63 – 0.82) 3.2E-07 1.12 (0.99 – 1.27) 7.5E-02 1.57 (1.41 – 1.74) 1.6E-18
IgG23_A2G Galactosylation per antenna on diantennary glycans 0.79 (0.68 – 0.90) 5.3E-04 0.38 (0.32 – 0.45) 1.9E-35 0.47 (0.42 – 0.53) 4.1E-40
IgG23_A2S Sialylation per antenna on diantennary glycans 0.86 (0.76 – 0.98) 2.3E-02 0.52 (0.45 – 0.60) 5.7E-21 0.57 (0.51 – 0.64) 2.4E-25
IgG23_A2GS Sialylation per galactose on diantennary glycans 1.02 (0.90 – 1.14) 8.0E-01 1.19 (1.05 – 1.35) 7.6E-03 1.11 (1.01 – 1.22) 2.9E-02

IgG4

IgG4_agal Fraction of agalactosylated glycans 1.30 (1.13 – 1.48) 1.2E-04 2.16 (1.84 – 2.54) 2.3E-24 1.62 (1.46 – 1.80) 3.7E-20
IgG4_digal Fraction of digalactosylated glycans 0.89 (0.78 – 1.01) 7.9E-02 0.53 (0.46 – 0.61) 2.8E-18 0.60 (0.53 – 0.67) 1.4E-21
IgG4_monogal Fraction of monogalactosylated glycans 0.69 (0.60 – 0.79) 2.0E-08 0.45 (0.38 – 0.53) 7.9E-26 0.68 (0.62 – 0.76) 6.9E-14
IgG4_sial Fraction of sialylated glycans 1.01 (0.89 – 1.14) 9.2E-01 0.68 (0.59 – 0.78) 2.2E-08 0.66 (0.60 – 0.74) 3.0E-15
IgG4_A2FB Bisection of diantennary glycans 0.79 (0.70 – 0.90) 3.5E-04 0.84 (0.73 – 0.96) 1.1E-02 0.97 (0.88 – 1.08) 5.9E-01
IgG4_A2FG Galactosylation per antenna on diantennary glycans 0.81 (0.71 – 0.92) 1.5E-03 0.48 (0.41 – 0.57) 2.2E-22 0.61 (0.55 – 0.68) 5.4E-21
IgG4_A2FS Sialylation per antenna on diantennary glycans 1.03 (0.90 – 1.17) 6.8E-01 0.70 (0.61 – 0.80) 1.3E-07 0.67 (0.60 – 0.74) 8.5E-15
IgG4_A2FGS Sialylation per galactose on diantennary glycans 1.38 (1.21 – 1.57) 8.5E-07 1.39 (1.22 – 1.60) 7.2E-07 1.00 (0.90 – 1.10) 9.3E-01
a

Derived glycosylation traits were calculated as described in Supp. Table 4.

b

To assess differences between HC and UC patients (HC = 0, UC = 1), HC and CD patients (HC = 0, CD = 1) and between UC and CD patients (UC = 0, CD = 1), logistic regression was performed, using age and sex as co-variables.

c

Displayed are the odds ratios (OR) and their 95 % confidence intervals (CI) for the ITA cohort.

d

p-values were indicated in bold when statistically significant after multiple testing correction (5% FDR). Underlined p-values indicate results that were replicated in the US cohort (Supp. Table 6., 8., and 10.).